Skye Bioscience Inc.(US:SKYE) Newsfile·2025-11-26 14:54Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Skye Biosciences, Inc. due to allegations of misleading statements regarding the effectiveness of its drug nimacimab, which led to significant financial losses for investors [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in Skye between November 4, 2024, and October 3, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Skye, with a deadline of January 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Skye - The complaint alleges that Skye and its executives violated federal securities laws by making false statements about nimacimab's effectiveness and overstating its clinical and commercial prospects [5]. - On October 6, 2025, Skye announced that its nimacimab did not achieve the primary endpoint of weight loss in a clinical study, leading to a 60% drop in stock price, closing at $1.90 per share [6]. Group 3: Investor Communication - Faruqi & Faruqi encourages anyone with information regarding Skye's conduct, including whistleblowers and former employees, to contact the firm [8].